Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial

Lancet Oncology

Volumn 6, Issue 6, 2005, Pages 369-376

  Reni, Michele ^a   Cordio, Stefano ^b   Milandri, Carlo ^b   Passoni, Paolo ^a   Bonetto, Elisa ^a   Oliani, Cristina ^c   Luppi, Gabriele ^d   Nicoletti, Roberto ^a   Galli, Laura ^a   Bordonaro, Roberto ^b   Passardi, Alessandro ^b   Zerbi, Alessandro ^a   Balzano, Gianpaolo ^a   Aldrighetti, Luca ^a   Staudacher, Carlo ^a   Villa, Eugenio ^a   Di Carlo, Valerio ^a  

^a Ctr of Cell and Molec Pharmacol   (Italy)

^b S Luigi Currò H Catania ^*  (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CISPLATINO TEVA; EPIRUBICIN; FARMARUBICINA; FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPENIA; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; ITALY; MALE; MIDDLE AGED; PALLIATIVE CARE; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 19944409357     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70175-3     Document Type: Article

References (29)

1. HA Burris 3rd MJ Moore J Andersen et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 1997 2403-2413
2. Berlin J.D. Catalano P. Thomas J.P. et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J. Clin. Oncol. 2002 20 3270-3275
3. MJ Moore J Hamm J Dancey et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 2003 3296-3302
4. Rocha Lima C.M.S. Green M.R. Rotche R. et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J. Clin. Oncol. 2004 22 3776-3783
5. Bramhall S.R Schultz J. Nemunaitis J. et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br. J. Cancer 2002 87 161-167
6. Bramhall S.R. Rosemurgy A. Brown P.D. for the Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial J. Clin. Oncol. 2001 19 3477-3355
7. Heinemann V. Quietzsch D. Gieseler F. et al. A phase III trial comparing gemcitabine plus cisplatin vs gemcitabine alone in advanced pancreatic adenocarcinoma Proc. Am. Soc. Clin. Oncol. 2003 22 abstr 1003
8. Van Cutsem E. van de Velde H. Karasek P. et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J. Clin. Oncol. 2004 22 1430-1438
9. O'Reilly E.M. Abou-Alfa G.K. Letorneau R. et al. A randomized phase III trial of DX-8951f (exatecan mesylate) and gemcitabine vs gemcitabine alone in advanced pancreatic cancer Proc. Am. Soc. Clin. Oncol. 2004 23 abstr 4006
10. DA Richards HL Kindler H Oettle et al. A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer Proc Am Soc Clin Oncol 23 2004 abstr 4007
11. C Louvet R Labianca P Hammel et al. GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non-resectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup phase III Proc Am Soc Clin Oncol 23 2004 abstr 4008
12. N Maisey I Chau D Cunningham et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer J Clin Oncol 20 2002 3130-3136
13. M Ducreux P Rougier JP Pignon et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma Ann Oncol 13 2002 1185-1191
14. M Tempero W Plunkett V Ruiz Van Haperen et al. Randomized phase II comparison of dose-intense gemcitabine: Thirthy minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 2003 3402-3408
15. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trial Group (NCIC-CTG). Proceedings of the 2005 Gastrointestinal Cancers Symposium Jan 27-29, 2005; Hollywood, FL, USA, 3: Abstr 77
16. Reni M. Passoni P. Panucci M.G. et al. Definitive results of phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma J. Clin. Oncol. 2001 19 2679-2686
17. LH Sobin C Wittekind eds. International Union Against Cancer. TNM classification of malignant tumours 5th edn. 1997 Wiley-Liss New York
18. B Fishman S Pasternak SL Wallenstein et al. The Memorial Pain Assessment Card: A valid instrument for the evaluation of cancer pain Cancer 60 1987 1151-1158
19. Ajani J.A. Welch S.R. Raber M.N. et al. Comprehensive criteria for assessing therapy-induced toxicity Cancer Invest. 1990 8 147-159
20. AB Miller B Hoogstraten M Staquet A Winkler Reporting results of cancer treatment Cancer 47 1981 207-214
21. D Fitzsimmons CD Johnson S George et al. Development of a disease specific quality of life questionnaire module to supplement the EORTC core cancer qol questionnaire, the QLQ-C30 in patients with pancreatic cancer Eur J Cancer 35 1999 939-941
22. P Fayers N Aaronson K Bjordal et al. EORTC QLQ scoring manual 3rd edn. 2001 European Organisation for Research and Treatment of Cancer Brussels
23. D Osoba G Rodrigues J et al. Myles Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1998 139-144
24. M Reni E Bonetto S Cordio et al. Quality of life outcome in advanced pancreatic adenocarcinoma: Results from a phase III trial Ann Oncol 15 2004 abstr 911
25. K Hoffman B Glimelius Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer Acta Oncol 37 1998 651-659
26. Reni M, Passoni P, Bonetto E, et al. Final results of a prospective trial of a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology, in press.
27. P Passoni M Reni A Zanello et al. Preliminary results of a phase II trial of PEFG (cisplatin, epirubicin, 5-fluorouracil, and gemcitabine) in advanced gallbladder, biliary tract, and ampulla of Vater adenocarcinoma Ann Oncol 13 2002 abst 724
28. Villa E. Reni M. Zanello A. et al. PEFG regimen (cisplatin, epirubicin, 5-fluorouracil continuous infusion, and gemcitabine) in advanced gastric adenocarcinoma Ann. Oncol. 2003 14 abstr D5
29. JR Johnson G Williams R Pazdur End points and United States Food and Drug Administration approval of oncology drugs J Clin Oncol 21 2003 1404-1411